Edwards Lifesciences vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Edwards Lifesciences Corp (EW)

Q3 202630 Jun – 18 Sep 2026

▲3▼1

Edwards Lifesciences: Strong TAVR Growth, CMS Coverage Expansion, and TMTT Ambitions

Q2 2026 Sales Growth and Raised Guidance Edwards reported Q2 2026 sales of $1.74 billion, up 12.5% year-over-year, with TAVR sales up 10.5% and TMTT up 44.8%. Management raised full-year 2026 sales growth guidance for TAVR, TMTT, and total company, signaling confidence in continued momentum. This strong performance and upbeat outlook push EW's price up as investors see accelerating growth.
This is a key new event that directly shows the company's financial health and future prospects, driving positive sentiment.
Updated CMS Coverage Decision for TAVR CMS updated its national coverage determination to ease patient access to TAVR, removing the coverage with evidence development requirement for symptomatic severe aortic stenosis and expanding coverage to asymptomatic severe cases. This regulatory change could enable 100-200 additional U.S. centers to perform TAVR, boosting demand for Edwards' core product and lifting EW's price.
This is a new regulatory catalyst that expands the addressable market for Edwards' main product, directly impacting future revenue.
TMTT Growth Plan Targeting $2 Billion by 2030 Edwards outlined a plan to exceed $2 billion in transcatheter mitral and tricuspid revenue by 2030, anchored by PASCAL, EVOQUE, and Sapien M3. This long-term growth initiative, combined with the CMS coverage expansion, reinforces the company's transcatheter ecosystem and supports a higher valuation, pushing EW's price up.
This new strategic target provides a clear long-term growth driver, enhancing investor confidence in future earnings.
$10 Million Penalty for Antitrust Violations Edwards must pay a $10 million penalty for antitrust violations related to its JC Medical acquisition, structuring payments to avoid mandatory antitrust review. The company must also establish a compliance program. This regulatory penalty creates a financial and reputational hit, weighing on EW's price.
This is a new negative event that introduces legal and financial risks, potentially dampening investor enthusiasm.

August 202630 Jun – 18 Sep 2026

▲3▼1

Edwards Lifesciences: Strong TAVR Growth, CMS Coverage Expansion, and TMTT Ambitions

Q2 2026 Sales Growth and Raised Guidance Edwards reported Q2 2026 sales of $1.74 billion, up 12.5% year-over-year, with TAVR sales up 10.5% and TMTT up 44.8%. Management raised full-year 2026 sales growth guidance for TAVR, TMTT, and total company, signaling confidence in continued momentum. This strong performance and upbeat outlook push EW's price up as investors see accelerating growth.
This is a key new event that directly shows the company's financial health and future prospects, driving positive sentiment.
Updated CMS Coverage Decision for TAVR CMS updated its national coverage determination to ease patient access to TAVR, removing the coverage with evidence development requirement for symptomatic severe aortic stenosis and expanding coverage to asymptomatic severe cases. This regulatory change could enable 100-200 additional U.S. centers to perform TAVR, boosting demand for Edwards' core product and lifting EW's price.
This is a new regulatory catalyst that expands the addressable market for Edwards' main product, directly impacting future revenue.
TMTT Growth Plan Targeting $2 Billion by 2030 Edwards outlined a plan to exceed $2 billion in transcatheter mitral and tricuspid revenue by 2030, anchored by PASCAL, EVOQUE, and Sapien M3. This long-term growth initiative, combined with the CMS coverage expansion, reinforces the company's transcatheter ecosystem and supports a higher valuation, pushing EW's price up.
This new strategic target provides a clear long-term growth driver, enhancing investor confidence in future earnings.
$10 Million Penalty for Antitrust Violations Edwards must pay a $10 million penalty for antitrust violations related to its JC Medical acquisition, structuring payments to avoid mandatory antitrust review. The company must also establish a compliance program. This regulatory penalty creates a financial and reputational hit, weighing on EW's price.
This is a new negative event that introduces legal and financial risks, potentially dampening investor enthusiasm.

Latest30 Jun – 18 Sep 2026

▲3▼1

Edwards Lifesciences: Strong TAVR Growth, CMS Coverage Expansion, and TMTT Ambitions

Q2 2026 Sales Growth and Raised Guidance Edwards reported Q2 2026 sales of $1.74 billion, up 12.5% year-over-year, with TAVR sales up 10.5% and TMTT up 44.8%. Management raised full-year 2026 sales growth guidance for TAVR, TMTT, and total company, signaling confidence in continued momentum. This strong performance and upbeat outlook push EW's price up as investors see accelerating growth.
This is a key new event that directly shows the company's financial health and future prospects, driving positive sentiment.
Updated CMS Coverage Decision for TAVR CMS updated its national coverage determination to ease patient access to TAVR, removing the coverage with evidence development requirement for symptomatic severe aortic stenosis and expanding coverage to asymptomatic severe cases. This regulatory change could enable 100-200 additional U.S. centers to perform TAVR, boosting demand for Edwards' core product and lifting EW's price.
This is a new regulatory catalyst that expands the addressable market for Edwards' main product, directly impacting future revenue.
TMTT Growth Plan Targeting $2 Billion by 2030 Edwards outlined a plan to exceed $2 billion in transcatheter mitral and tricuspid revenue by 2030, anchored by PASCAL, EVOQUE, and Sapien M3. This long-term growth initiative, combined with the CMS coverage expansion, reinforces the company's transcatheter ecosystem and supports a higher valuation, pushing EW's price up.
This new strategic target provides a clear long-term growth driver, enhancing investor confidence in future earnings.
$10 Million Penalty for Antitrust Violations Edwards must pay a $10 million penalty for antitrust violations related to its JC Medical acquisition, structuring payments to avoid mandatory antitrust review. The company must also establish a compliance program. This regulatory penalty creates a financial and reputational hit, weighing on EW's price.
This is a new negative event that introduces legal and financial risks, potentially dampening investor enthusiasm.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest28 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.